Obviously the dream for all longs would involve two or more big pharmas fighting over little ol' Resverlogix.....I can't think of a better scenario playing out for driving shareholder value.

Obviously if Apabetalone succeeds in achieving its primary and secondary end points it should reasonably be expected to have a negative impact on drugs like Crestor. But at the same time, even if RVX-208 blows the doors off with RRR, I expect adoption of it would be slow in the medical community....its that saying about "old habits dying hard". Doctors get used to perscribing one medication and the new kid on the block would take time to gain traction imo.

Its all fun specualtion right now....hopefully by Tuesday we'll have some solid info to discuss and can put off guessing for a while.

Here's a question for all and Sundry.....In the Oct 6th PR it said:

"A notice of meeting and management information circular containing the matters to be considered at the meeting *will be delivered to shareholders and filed on SEDAR at www.sedar.com on or before November 15, 2016...." (*my bolding and emphasis)

Has anyone received anything in the mail? I haven't. Does "be delivered to"....does it mean by mail or could it be delivered via NR?